Cancer is a life-threatening disease that imposes an economic burden on society. Diagnosing and treating carcinoma is a great challenge due to its complexity and therapeutic resistance. Despite recent advances in treatment strategies, such as immunotherapy and targeted therapy, the survival rate of cancer patients has reached plateau levels.
Tumor cells often exhibit primary or acquired resistance to therapy, consequently leading to treatment failure. Thus, besides the discovery of new anticancer targets, the identification of prognostic and predictive biomarkers becomes a crucial part of drug development nowadays, especially in the era of targeted therapy. Interestingly, the research about epigenetic alterations in cancer development and progression has recently led to new paradigms paving the way for innovative therapeutic strategies but also for new biomarkers.
This Research Topic aims to focus on novel biomarkers to be associated with anti-cancer drugs, including those related to the epigenetic regulation of cancer and drug response.
Cancer is a life-threatening disease that imposes an economic burden on society. Diagnosing and treating carcinoma is a great challenge due to its complexity and therapeutic resistance. Despite recent advances in treatment strategies, such as immunotherapy and targeted therapy, the survival rate of cancer patients has reached plateau levels.
Tumor cells often exhibit primary or acquired resistance to therapy, consequently leading to treatment failure. Thus, besides the discovery of new anticancer targets, the identification of prognostic and predictive biomarkers becomes a crucial part of drug development nowadays, especially in the era of targeted therapy. Interestingly, the research about epigenetic alterations in cancer development and progression has recently led to new paradigms paving the way for innovative therapeutic strategies but also for new biomarkers.
This Research Topic aims to focus on novel biomarkers to be associated with anti-cancer drugs, including those related to the epigenetic regulation of cancer and drug response.